{"id":"W4412493533","doi":"10.1007/s12325-025-03258-9","title":"Real-World Evidence for Ixekizumab in the Treatment of Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis: Systematic Literature Review 2022–2023","year":2025,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Eli Lilly (Canada)","funders":"Novartis Pharma; Samsung; LEO Pharma; Swedish Orphan Biovitrum; Chugai Pharmaceutical; Celltrion; UCB Pharma; Regeneron Pharmaceuticals; Baxalta; Biogen; Celgene; Cilag; Mylan; Gilead Sciences; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ixekizumab; Medicine; Secukinumab; Psoriatic arthritis; Psoriasis; Dermatology; Ustekinumab; Quality of life (healthcare); Internal medicine; Physical therapy; Adalimumab; Rheumatoid arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006462998,0.000726152,0.00487633,0.0004066117,0.0001100137,0.00004133991,0.0002610779,0.0001959902,0.00001955092],"category_scores_gemma":[0.0002738571,0.000436177,0.0006892419,0.001421195,0.0001440545,0.0002153876,0.00002656668,0.0002536756,0.000002841049],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003047112,"about_ca_system_score_gemma":0.0001798219,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007996391,"about_ca_topic_score_gemma":0.001721648,"domain_scores_codex":[0.9961925,0.000589654,0.001672495,0.0007286954,0.000377848,0.0004388641],"domain_scores_gemma":[0.9958571,0.002498034,0.0006347121,0.0008401411,0.0001100636,0.00006001028],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0001611387,0.0003205518,0.000009743354,0.3279064,0.0002050086,0.0001784111,0.0002570224,5.795746e-8,3.097909e-8,0.0007984765,0.00006102176,0.6701021],"study_design_scores_gemma":[0.003511603,0.001297671,0.00001483959,0.6396896,0.0006942766,0.0001196239,0.0000495942,2.963502e-7,5.605957e-7,0.0002928635,0.3541296,0.0001994396],"study_design_candidate":"systematic_review","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00001475887,0.9855891,0.000001681801,0.0001387389,0.0006374352,0.01292668,0.0003077488,0.00002004612,0.0003637996],"genre_scores_gemma":[0.00001937242,0.99097,0.0002275818,0.0001905954,0.000222415,0.007782751,0.0002371917,0.00004706703,0.0003029869],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.6699027,"threshold_uncertainty_score":0.999809,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04201158268867548,"score_gpt":0.3994908874577577,"score_spread":0.3574793047690822,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}